Catalyst Pharmaceuticals (CPRX) News Today $23.53 -0.76 (-3.13%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$23.80 +0.27 (+1.15%) As of 06/13/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CPRX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)GAMMA Investing LLC raised its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 2,959.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 67,682 shares of the biopharmaceutical compJune 15 at 3:38 AM | marketbeat.comPreethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals StockJune 14 at 2:49 AM | benzinga.comPreethi Sundaram Sells 1,600 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) StockJune 13 at 8:42 AM | insidertrades.comStanley Laman Group Ltd. Invests $3.50 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Stanley Laman Group Ltd. purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 144,428 shares of the biopharmaceuticalJune 13 at 8:41 AM | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Preethi Sundaram Sells 1,600 SharesCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Preethi Sundaram sold 1,600 shares of Catalyst Pharmaceuticals stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the sale, the insider now owns 41,081 shares of the company's stock, valued at $1,085,360.02. This trade represents a 3.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.June 12 at 5:38 PM | marketbeat.comInsider Selling: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells 2,324 Shares of StockCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) insider Preethi Sundaram sold 2,324 shares of the firm's stock in a transaction on Tuesday, June 10th. The shares were sold at an average price of $26.41, for a total value of $61,376.84. Following the transaction, the insider now directly owns 42,681 shares of the company's stock, valued at $1,127,205.21. This represents a 5.16% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.June 12 at 5:38 PM | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Down 5.2% - Here's What HappenedCatalyst Pharmaceuticals (NASDAQ:CPRX) Shares Down 5.2% - Should You Sell?June 12 at 2:47 PM | marketbeat.comDirector Of Catalyst Pharmaceuticals Sold $5.22M In StockJune 11, 2025 | benzinga.comMetsera Shows Rising Price Performance With Jump To 92 RS RatingJune 11, 2025 | msn.com19,000 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Wesbanco Bank Inc.Wesbanco Bank Inc. acquired a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 19,000 shares of the biopharmaceutical company's stock, valued at approximatJune 11, 2025 | marketbeat.comARS Pharmaceuticals Earns Relative Strength Rating UpgradeJune 9, 2025 | msn.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 12-Month High - What's Next?Catalyst Pharmaceuticals (NASDAQ:CPRX) Reaches New 1-Year High - What's Next?June 9, 2025 | marketbeat.com117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLCBridge City Capital LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 117,374 shares of the biopharmaceuticalJune 9, 2025 | marketbeat.comCatalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded by Cantor Fitzgerald to "Strong-Buy" RatingJune 8, 2025 | americanbankingnews.comCantor Fitzgerald Upgrades Catalyst Pharmaceuticals (NASDAQ:CPRX) to Strong-BuyCantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday.June 6, 2025 | marketbeat.comRichard P Slaughter Associates Inc Sells 37,912 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Richard P Slaughter Associates Inc lessened its stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 25.4% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 111,494 shares of theJune 4, 2025 | marketbeat.comCatalyst Pharmaceuticals (NasdaqCM:CPRX) Appoints Dr. William Andrews As New Chief Medical OfficerJune 4, 2025 | finance.yahoo.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock Holdings Increased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLCUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 11.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutioJune 3, 2025 | marketbeat.comCatalyst Pharmaceuticals Announces Appointment of William T. Andrews, MD, FACP as Chief Medical OfficerJune 2, 2025 | globenewswire.comUniversal Beteiligungs und Servicegesellschaft mbH Invests $3.73 Million in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Universal Beteiligungs und Servicegesellschaft mbH bought a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 178,850 shares of the biopharmaceuJune 2, 2025 | marketbeat.comMackenzie Financial Corp Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Mackenzie Financial Corp lifted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 132.9% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 34,531 shares of the biopharmaceutical companyJune 2, 2025 | marketbeat.comWhat is Zacks Research's Forecast for CPRX FY2025 Earnings?Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Equities research analysts at Zacks Research boosted their FY2025 EPS estimates for shares of Catalyst Pharmaceuticals in a research report issued to clients and investors on Wednesday, May 28th. Zacks Research analyst A. Chakraborty noJune 2, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Consensus Recommendation of "Buy" from BrokeragesCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) has received a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rJune 1, 2025 | marketbeat.comCatalyst: Solid Business Model Propels Growth For This Buy And Build PharmaMay 31, 2025 | seekingalpha.comZacks Research Issues Positive Estimate for CPRX EarningsCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) - Investment analysts at Zacks Research upped their Q2 2025 earnings estimates for Catalyst Pharmaceuticals in a research note issued to investors on Wednesday, May 28th. Zacks Research analyst A. Chakraborty now forecasts that the biophaMay 31, 2025 | marketbeat.comSquarepoint Ops LLC Increases Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Squarepoint Ops LLC lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 38.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 111,705 shares of the biopharmaceuticalMay 30, 2025 | marketbeat.com14,669 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Armis Advisers LLCArmis Advisers LLC bought a new position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,669 shares of the biopharmaceuMay 28, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Buys Shares of 18,173 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)D. E. Shaw & Co. Inc. purchased a new position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor purchased 18,173 shares of the biopharmaceutical company's stock, valued at approximaMay 28, 2025 | marketbeat.comVoloridge Investment Management LLC Decreases Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Voloridge Investment Management LLC cut its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 30.7% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 531,836 shares of the biopharmMay 27, 2025 | marketbeat.comProShare Advisors LLC Grows Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)ProShare Advisors LLC boosted its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 44.5% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 33,699 shares of the biopharmaceutical compMay 27, 2025 | marketbeat.com85,059 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Acquired by Castlekeep Investment Advisors LLCCastlekeep Investment Advisors LLC purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 85,059 shares of the biopharmaceuticaMay 26, 2025 | marketbeat.comNeo Ivy Capital Management Purchases New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Neo Ivy Capital Management purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 35,652 shares of the biopharmaceutical companMay 26, 2025 | marketbeat.comWoodline Partners LP Sells 53,489 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Woodline Partners LP trimmed its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 17.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 252,969 shares of the biopharmaceutical company's stock after selling 53,48May 26, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Millennium Management LLCMillennium Management LLC reduced its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 7.0% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 520,778 shares of the bMay 26, 2025 | marketbeat.comCetera Investment Advisers Grows Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Cetera Investment Advisers grew its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 35.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,114 shares of the biopharmaceuticalMay 26, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Position Decreased by Jane Street Group LLCJane Street Group LLC decreased its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 90.7% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 37,251 shares of the biMay 26, 2025 | marketbeat.comNuveen Asset Management LLC Boosts Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Nuveen Asset Management LLC boosted its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 14.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,304,391 shares of the biopharmaceutical company's stockMay 25, 2025 | marketbeat.com20,917 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Teza Capital Management LLCTeza Capital Management LLC purchased a new stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 20,917 shares of the biopharmaceuticMay 22, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Acquired by Man Group plcMan Group plc increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 24.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 315,817 shares of the biopharmaceutical company's stock after acMay 22, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Deutsche Bank AGDeutsche Bank AG reduced its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 65.3% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 200,395 shares of the biopharmaceutical company's stock after selling 377,813 shares during the quartMay 22, 2025 | marketbeat.comTema Etfs LLC Acquires Shares of 11,352 Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Tema Etfs LLC acquired a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 11,352 shares of the biopharmaceuticaMay 21, 2025 | marketbeat.comLazard Asset Management LLC Purchases 46,318 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Lazard Asset Management LLC increased its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 58.6% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 125,343 shares of the biopharmaceutiMay 19, 2025 | marketbeat.comJanus Henderson Group PLC Increases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Janus Henderson Group PLC boosted its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 32.2% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 476,023 shares of the biopharmaceutical company's stMay 19, 2025 | marketbeat.comBank of America Corp DE Raises Stock Holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Bank of America Corp DE raised its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 139.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 1,568,791 shares of the biopharmaceutical company's stock after buying an adMay 19, 2025 | marketbeat.comBNP Paribas Financial Markets Has $2.67 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)BNP Paribas Financial Markets lessened its holdings in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 16.7% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 127,679 shares of the biopharmaceutical company's stock after selling 25,571 sMay 18, 2025 | marketbeat.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Gary Ingenito Sells 44,000 SharesMay 16, 2025 | insidertrades.comCatalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by Jacobs Levy Equity Management Inc.Jacobs Levy Equity Management Inc. lowered its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 13.7% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 912,999 shares of the biopharmaceutical company's stock afterMay 15, 2025 | marketbeat.comThe Strong Earnings Posted By Catalyst Pharmaceuticals (NASDAQ:CPRX) Are A Good Indication Of The Strength Of The BusinessMay 14, 2025 | finance.yahoo.comIntegral Health Asset Management LLC Cuts Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Integral Health Asset Management LLC trimmed its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 25.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 300,000 shares of theMay 14, 2025 | marketbeat.comAlgert Global LLC Boosts Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)Algert Global LLC lifted its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 185.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 47,920 shares of the biopharmaceutical company's stock after bMay 13, 2025 | marketbeat.com Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address CPRX Media Mentions By Week CPRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CPRX News Sentiment▼0.720.89▲Average Medical News Sentiment CPRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CPRX Articles This Week▼167▲CPRX Articles Average Week Get Catalyst Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CPRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies MRNA News ASND News VTRS News QGEN News BPMC News ROIV News RVMD News BBIO News ELAN News VRNA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CPRX) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredHere’s How to Claim Your Stake in Elon’s Private Company, xAIEven though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks...Brownstone Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendI just uncovered a strategy that could pay out up to $7,013 every month—without needing a traditional dividend...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Catalyst Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Catalyst Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CPRX Stock Free CPRX Stock Alerts